NKTR - Nektar Therapeutics

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
33.55
+0.48 (+1.45%)
As of 11:10AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close33.07
Open33.21
Bid33.46 x 800
Ask33.48 x 800
Day's Range33.21 - 34.11
52 Week Range29.22 - 92.17
Volume301,737
Avg. Volume1,666,485
Market Cap5.848B
Beta (3Y Monthly)3.42
PE Ratio (TTM)9.35
EPS (TTM)3.59
Earnings DateAug 6, 2019 - Aug 12, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est69.91
Trade prices are not sourced from all markets
  • Nektar (NKTR) Announces Formation of CNS-Focused Subsidiary
    Zacks1 hour ago

    Nektar (NKTR) Announces Formation of CNS-Focused Subsidiary

    Nektar (NKTR) forms wholly-owned subsidiary, Inheris Biopharm, focusing on CNS pipeline. The subsidiary will mainly be responsible for potential commercialization of under review pain drug, NKTR-181.

  • Why this pain-killing opioid is spinning into a new company
    American City Business Journals18 hours ago

    Why this pain-killing opioid is spinning into a new company

    Nektar's wholly owned subsidiary might relieve some pain if NKTR-181 finds it tough to win a recommendation in August from an FDA advisory committee yet also provide financial upside if its unique opioid is approved.

  • PR Newswireyesterday

    Nektar Announces the Launch of Inheris Biopharma, Inc.

    SAN FRANCISCO, May 23, 2019 /PRNewswire/ -- Nektar Therapeutics (NKTR) today announced the formation of Inheris Biopharma, Inc., a wholly-owned subsidiary of Nektar and a CNS-focused company. Inheris will also lead development of several Nektar preclinical CNS assets.

  • Benzinga2 days ago

    Jim Cramer Weighs In On Nektar, L Brands And More

    On CNBC's "Mad Money Lightning Round,"  Jim Cramer said Nektar Therapeutics (NASDAQ: NKTR ) is pretty good, but it's a total spec on oncology and pain. He would rather buy Novartis AG (NYSE: ...

  • Cramer's lightning round: McDonald's is 'one of the greatest stocks of our time'
    CNBC3 days ago

    Cramer's lightning round: McDonald's is 'one of the greatest stocks of our time'

    Jim Cramer takes calls and gives his thoughts on McDonald's, Nektar Technologies, L Brands, and more.

  • 6 Positions the Vanguard Health Care Fund Continues to Increase
    GuruFocus.com8 days ago

    6 Positions the Vanguard Health Care Fund Continues to Increase

    CVS Health tops the list

  • PR Newswire9 days ago

    Nektar Therapeutics Announces Five Accepted Abstracts at 2019 American Society of Clinical Oncology's (ASCO) Annual Meeting

    SAN FRANCISCO , May 15, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced five abstracts accepted for presentation at the 55 th Annual Meeting of the American Society of Clinical ...

  • Thomson Reuters StreetEvents9 days ago

    Edited Transcript of NKTR earnings conference call or presentation 8-May-19 9:00pm GMT

    Q1 2019 Nektar Therapeutics Earnings Call

  • 3 Small Drug Stocks Poised to Beat Q1 Earnings Estimates
    Zacks14 days ago

    3 Small Drug Stocks Poised to Beat Q1 Earnings Estimates

    So far this earnings season, the going seems to be good for the medical sector. Let us take a glance at a few small drug companies, which are likely to beat on Q1 earnings.

  • This Biotech Stock Is Flying As Cancer Update, Opioid Approval Loom
    Investor's Business Daily15 days ago

    This Biotech Stock Is Flying As Cancer Update, Opioid Approval Loom

    Nektar Therapeutics stock popped Thursday after the company said it would present new data for a Bristol-partnered cancer treatment in June. It's near approval for a next-generation opioid.

  • Nektar (NKTR) Q1 Earnings & Revenues Beat, Decline Y/Y
    Zacks15 days ago

    Nektar (NKTR) Q1 Earnings & Revenues Beat, Decline Y/Y

    Nektar's (NKTR) earnings and sales beat estimates in the first quarter. The company is progressing well with its pipeline candidates.

  • What You'll Want to Know About Nektar Therapeutics' Q1 Earnings Results
    Motley Fool15 days ago

    What You'll Want to Know About Nektar Therapeutics' Q1 Earnings Results

    Nektar's Q1 financial results weren't anything to get excited about. But good things could be on the way for the biotech.

  • Nektar Therapeutics (NKTR) Q1 2019 Earnings Call Transcript
    Motley Fool15 days ago

    Nektar Therapeutics (NKTR) Q1 2019 Earnings Call Transcript

    NKTR earnings call for the period ending March 31, 2019.

  • Nektar Therapeutics (NKTR) Reports Q1 Loss, Tops Revenue Estimates
    Zacks16 days ago

    Nektar Therapeutics (NKTR) Reports Q1 Loss, Tops Revenue Estimates

    Nektar (NKTR) delivered earnings and revenue surprises of 4.23% and 10.90%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press16 days ago

    Nektar: 1Q Earnings Snapshot

    The San Francisco-based company said it had a loss of 68 cents per share. The results surpassed Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research was ...

  • PR Newswire16 days ago

    Nektar Therapeutics Reports Financial Results for the First Quarter of 2019

    SAN FRANCISCO , May 8, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the first quarter ended March 31, 2019 . Cash and investments in marketable securities ...

  • TheStreet.com17 days ago

    Nektar Therapeutics Expected to Lose 69 Cents a Share

    is expected to report a quarterly loss of 69 cents a share on sales of $27.7 million after the market closes on Wednesday, based on a FactSet survey of 11 analysts. The stock has fallen 19.4% since the company last reported earnings on Feb. 28. Nektar Therapeutics is currently trading at a price-to-forward-earnings ratio of -11.7 based on the 12-month estimates of 12 analysts surveyed by FactSet.

  • What's in the Cards for Nektar (NKTR) This Earnings Season?
    Zacks17 days ago

    What's in the Cards for Nektar (NKTR) This Earnings Season?

    The focus will be on Nektar Therapeutics' (NKTR) pipeline progress when the company reports first-quarter results.

  • Markit17 days ago

    See what the IHS Markit Score report has to say about Nektar Therapeutics.

    Nektar Therapeutics NASDAQ/NGS:NKTRView full report here! Summary * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is moderate * Economic output in this company's sector is expanding Bearish sentimentShort interest | NeutralShort interest is moderate for NKTR with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative and may be weakening. The net inflows of $4.18 billion over the last one-month into ETFs that hold NKTR are among the lowest of the last year and appear to be slowing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Earnings Preview: Nektar Therapeutics (NKTR) Q1 Earnings Expected to Decline
    Zacks22 days ago

    Earnings Preview: Nektar Therapeutics (NKTR) Q1 Earnings Expected to Decline

    Nektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • PR Newswire23 days ago

    Nektar to Announce Financial Results for the First Quarter 2019 on Wednesday, May 8, 2019, After Close of U.S.-Based Financial Markets

    SAN FRANCISCO , May 1, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter 2019 on Wednesday, May 8, 2019 , after the close of U.S.-based financial ...

  • 3 Top Biotech Stocks to Buy Right Now
    Motley Fool26 days ago

    3 Top Biotech Stocks to Buy Right Now

    The future looks incredibly bright for these three businesses.

  • Reuterslast month

    S&P 500 closes at record high, even as EPS growth stagnates

    The widely followed S&P 500 marked its highest ever close, beating its previous record closing high on Sept. 20, and the Nasdaq beat its Aug. 29 all-time closing high. The S&P 500 has rallied 25% from Dec. 24, reversing a steep selloff caused by fears of higher interest rates and uncertainty around U.S. President Donald Trump's trade war with Beijing. The S&P 500 has slightly underperformed European stocks over the same time period.

  • Were Hedge Funds Right About Souring On Nektar Therapeutics (NKTR)?
    Insider Monkeylast month

    Were Hedge Funds Right About Souring On Nektar Therapeutics (NKTR)?

    Hedge funds are known to underperform the bull markets but that's not because they are bad at investing. Truth be told, most hedge fund managers and other smaller players within this industry are very smart and skilled investors. Of course, they may also make wrong bets in some instances, but no one knows what the […]

  • These 3 Falling Knives Are Expected to Outperform
    GuruFocus.comlast month

    These 3 Falling Knives Are Expected to Outperform

    Further, these companies have a GuruFocus financial strength rating of at least 5 out of 10, reducing the bankruptcy rate risk, which is quite common among falling knives. Warning! GuruFocus has detected 2 Warning Signs with NKTR. The closing price on Thursday was 22.5% off the 52-week low of $29.22 and 193% from the 52-week high of $104.88.